EUVIMEDEUVIMED entdecken
Multizentrische Studie

Optimal timing for initiating androgen receptor signaling inhibitor therapy in patients with nonmetastatic castration-resistant prostate cancer: a multicenter collaborative study

Shuhei Hara, Fumihiko Urabe iD, Kojiro Tashiro, Yuma Goto, Yuya Iwamoto, Takashi Ohtsuka, Wataru Fukuokaya, Yu Imai, Kosuke Iwatani, Mahito Atsuta, Keiichiro Mori, Taro Igarashi und 12 weitere

Japanese Journal of Clinical Oncology · 2025

DOI: 10.1093/jjco/hyae146 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Shuhei Hara und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Jikei University School of Medicine, 3-25-9, Nishi-Shimbashi, Minato-ku, Tokyo 105-8461, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Androgen Receptor Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We determined the optimal timing for initiating androgen receptor signaling inhibitor (ARSI) therapy in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and assessed its impact on oncological outcomes. Materials and methods This retrospective study included 145 nmCRPC patients who received enzalutamide, apalutamide or darolutamide at the Jikei University Hospital or its affiliated institutions between May 2014 and November 2022. Patients were stratified based on prostate-specific antigen (PSA) doubling time (PSADT) at CRPC diagnosis and PSA levels at ARSI initiation. Oncological outcomes, including progression-free survival (PFS), metastasis-free survival (MFS), cancer-specific survival and overall survival, were assessed using the Kaplan–Meier curve and Cox regression analysis.

Results

The median age of the patients was 73 (interquartile range [IQR]: 52–88) years, and the median follow-up duration was 36 (IQR: 2–104) months. The median PSA level at ARSI initiation was 5.4 (IQR: 2.2–48) ng/ml, and 44.8% of patients had a PSADT <3 months. Multivariate analysis revealed that PSADT and PSA levels at ARSI initiation were independent MFS predictors. Patients with a PSADT ≤3 months and a PSA level ≥5.4 ng/ml experienced significantly reduced PFS and MFS. Notably, ARSI initiation at a PSA level ≥5.4 ng/ml was associated with worse outcomes, suggesting the potential benefit of earlier intervention.

Conclusions

Patients with rapid PSADT are at increased risk of early disease progression, suggesting that immediate treatment may be warranted. In addition, initiating therapy at a PSA level <5.4 ng/ml may be associated with improved patient outcomes in patients with low PSADT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantAndrogen Receptor AntagonistsHumansMaleAgedMiddle AgedRetrospective StudiesAged, 80 and overNitrilesProstate-Specific AntigenReceptors, AndrogenBenzamidesThiohydantoinsPhenylthiohydantoinSignal TransductionProgression-Free SurvivalPyrazoles

Stichwörter der Autor:innen

PSA doubling timeinitiation of ARSInonmetastatic castration-resistant prostate canceroptimal timing

Substanzen

Androgen Receptor AntagonistsNitrilesProstate-Specific AntigenapalutamideReceptors, AndrogenenzalutamideBenzamidesThiohydantoinsdarolutamidePhenylthiohydantoin

Autor:innen und Institutionen

  • Department of Urology, The Jikei University School of Medicine, 3-25-9, Nishi-Shimbashi, Minato-ku, Tokyo 105-8461, Japan.
  • Department of Urology, Jikei Katsushika Medical Center, 6-41-2, Aoto, Katsushika-ku, Tokyo, 125-8506, Japan.
  • Department of Urology, Atsugi City Hospital, 1-16-36, Mizuhiki, Atsugi-shi, Kanagawa 243-8588, Japan.
  • Department of Urology, Fuji City General Hospital, 50, Takashima-cho, Fuji-shi, Shizuoka 417-8567, Japan.
  • Department of Urology, Jikei Kashiwa Hospital, 163-1, Kashiwashita, Kashiwa-Shi, Chiba 277-8567, Japan.
  • Toneri Urology Clinic, 1-11-17, Toneri, Adachi-ku, Tokyo 121-0831, Japan.

ORCID-Profile: Fumihiko Urabe, Shunsuke Tsuzuki

Zitieren

APA

Hara, S., Urabe, F., Tashiro, K., Goto, Y., Iwamoto, Y., Ohtsuka, T., Fukuokaya, W., Imai, Y., Iwatani, K., Atsuta, M., Mori, K., Igarashi, T., Aikawa, K., Yanagisawa, T., Kimura, S., Murakami, M., Tsuzuki, S., Yanada, B. A., Hata, K., …, & JIKEI-YAYOI Collaborative Group (2025). Optimal timing for initiating androgen receptor signaling inhibitor therapy in patients with nonmetastatic castration-resistant prostate cancer: a multicenter collaborative study. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae146

Vancouver

Hara S, Urabe F, Tashiro K, Goto Y, Iwamoto Y, Ohtsuka T, et al. Optimal timing for initiating androgen receptor signaling inhibitor therapy in patients with nonmetastatic castration-resistant prostate cancer: a multicenter collaborative study. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyae146

BibTeX
@article{Hara2025,
  author = {Hara, Shuhei and Urabe, Fumihiko and Tashiro, Kojiro and Goto, Yuma and Iwamoto, Yuya and Ohtsuka, Takashi and Fukuokaya, Wataru and Imai, Yu and Iwatani, Kosuke and Atsuta, Mahito and Mori, Keiichiro and Igarashi, Taro and Aikawa, Koichi and Yanagisawa, Takafumi and Kimura, Shoji and Murakami, Masaya and Tsuzuki, Shunsuke and Yanada, Brendan A and Hata, Kenichi and Furuta, Akira and Yamada, Hiroki and Miki, Jun and Kimura, Takahiro and JIKEI-YAYOI Collaborative Group, JIKEI-YAYOI Collaborative Group},
  title = {Optimal timing for initiating androgen receptor signaling inhibitor therapy in patients with nonmetastatic castration-resistant prostate cancer: a multicenter collaborative study},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1093/jjco/hyae146}
}
Kostenlos starten →